Literature DB >> 21573909

Malignant pleural mesothelioma.

Siva Raja1, Sudish C Murthy, David P Mason.   

Abstract

Malignant pleural mesothelioma (MPM) is a relatively rare thoracic malignancy accounting for about 2000-3000 new cases per year. This cancer has been increasing in incidence and is strongly associated with asbestos exposure. Also, it is characterized by insidious growth and clinical presentation at an advanced stage of disease. In the past, the treatment of this disease was limited to marginally effective chemotherapy and morbid surgery. This review explores the clinical presentation of MPM, its diagnostic approach and the relevant and recent studies that define the role of chemotherapy, radiation, and various surgical options. Currently, even with aggressive surgical interventions and multimodality strategies, cure remains elusive, although life prolongation has been achieved. Additionally, promising new therapies and interventions that are currently being studied are introduced in this review.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21573909     DOI: 10.1007/s11912-011-0177-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  38 in total

1.  Extended surgical staging for potentially resectable malignant pleural mesothelioma.

Authors:  David C Rice; Jeremy J Erasmus; Craig W Stevens; Ara A Vaporciyan; Judy S Wu; Anne S Tsao; Garrett L Walsh; Stephen G Swisher; Wayne L Hofstetter; Nelson G Ordonez; W Roy Smythe
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

Review 2.  Pathologic evaluation of malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Joseph M Corson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2009

3.  Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.

Authors:  D B Schneider; C Clary-Macy; S Challa; K C Sasse; S H Merrick; R Hawkins; G Caputo; D Jablons
Journal:  J Thorac Cardiovasc Surg       Date:  2000-07       Impact factor: 5.209

Review 4.  Translational therapies for malignant pleural mesothelioma.

Authors:  Carmen Belli; Santosh Anand; Gianfranco Tassi; Dean Fennell; Luciano Mutti
Journal:  Expert Rev Respir Med       Date:  2010-04       Impact factor: 3.772

5.  Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.

Authors:  Jeremy J Erasmus; Mylene T Truong; W Roy Smythe; Reginald F Munden; Edith M Marom; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Bradley S Sabloff; Lyle D Broemeling; Craig W Stevens; Katherine M Pisters; Donald A Podoloff; Homer A Macapinlac
Journal:  J Thorac Cardiovasc Surg       Date:  2005-06       Impact factor: 5.209

6.  Lymphocytic infiltration of pleural mesothelioma and its significance for survival.

Authors:  R A Leigh; I Webster
Journal:  S Afr Med J       Date:  1982-06-26

7.  Thirty-two cases of mesothelioma in Victoria, Australia: a retrospective survey related to occupational asbestos exposure.

Authors:  J E Milne
Journal:  Br J Ind Med       Date:  1976-05

8.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.

Authors:  David J Sugarbaker; Michael T Jaklitsch; Raphael Bueno; William Richards; Jeanne Lukanich; Steven J Mentzer; Yolonda Colson; Phillip Linden; Michael Chang; Leah Capalbo; Elizabeth Oldread; Siyamek Neragi-Miandoab; Scott J Swanson; Lambros S Zellos
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

9.  Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.

Authors:  J D Lee; S Perez; H J Wang; R A Figlin; E C Holmes
Journal:  J Surg Oncol       Date:  1995-12       Impact factor: 3.454

10.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

View more
  14 in total

1.  Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Authors:  Nicholas Veomett; Tao Dao; Hong Liu; Jingyi Xiang; Dmitry Pankov; Leonid Dubrovsky; Joseph A Whitten; Sun-Mi Park; Tatyana Korontsvit; Victoria Zakhaleva; Emily Casey; Michael Curcio; Michael G Kharas; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

2.  Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.

Authors:  Tapan K Nayak; Marcelino Bernardo; Diane E Milenic; Peter L Choyke; Martin W Brechbiel
Journal:  Radiology       Date:  2013-01-17       Impact factor: 11.105

3.  Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Authors:  Tao Dao; Su Yan; Nicholas Veomett; Dmitry Pankov; Liang Zhou; Tatyana Korontsvit; Andrew Scott; Joseph Whitten; Peter Maslak; Emily Casey; Taochao Tan; Hong Liu; Victoria Zakhaleva; Michael Curcio; Ekaterina Doubrovina; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Sci Transl Med       Date:  2013-03-13       Impact factor: 17.956

4.  Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Authors:  Lindsay A Marek; Trista K Hinz; Anne von Mässenhausen; Kyle A Olszewski; Emily K Kleczko; Diana Boehm; Mary C Weiser-Evans; Raphael A Nemenoff; Hans Hoffmann; Arne Warth; Joseph M Gozgit; Sven Perner; Lynn E Heasley
Journal:  Mol Cancer Res       Date:  2014-06-25       Impact factor: 5.852

5.  Current status of malignant mesothelioma with liver involvement in China: A brief report and review of the literature.

Authors:  Di Zhou; Zhiwei Quan; Jiandong Wang
Journal:  Intractable Rare Dis Res       Date:  2018-05

6.  Cerebral Metastasis of a Malignant Pleural Mesothelioma: A Case Report and Review of the Literature.

Authors:  Aswin Chari; Angelos G Kolias; Kieren Allinson; Thomas Santarius
Journal:  Cureus       Date:  2015-01-15

7.  Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.

Authors:  Petra C Schuberth; Christian Hagedorn; Shawn M Jensen; Pratiksha Gulati; Maries van den Broek; Axel Mischo; Alex Soltermann; Astrid Jüngel; Osiris Marroquin Belaunzaran; Rolf Stahel; Christoph Renner; Ulf Petrausch
Journal:  J Transl Med       Date:  2013-08-12       Impact factor: 5.531

8.  Hesperidin Induces Apoptosis by Inhibiting Sp1 and Its Regulatory Protein in MSTO-211H Cells.

Authors:  Kyung-Ae Lee; Sang-Han Lee; Yong-Jin Lee; Seung Mi Baeg; Jung-Hyun Shim
Journal:  Biomol Ther (Seoul)       Date:  2012-05       Impact factor: 4.634

9.  Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.

Authors:  Hio Chung Kang; Hong Kwan Kim; Sharon Lee; Pedro Mendez; James Wansoo Kim; Gavitt Woodard; Jun-Hee Yoon; Kuang-Yu Jen; Li Tai Fang; Kirk Jones; David M Jablons; Il-Jin Kim
Journal:  Oncotarget       Date:  2016-02-16

10.  Malignant Peritoneum Mesothelioma with Hepatic Involvement: A Single Institution Experience in 5 Patients and Review of the Literature.

Authors:  Shan-Shan Su; Guo-Qi Zheng; Ya-Gang Liu; Yue-Feng Chen; Zhao-Wei Song; Shu-Jing Yu; Ning-Ning Sun; Yu-Xin Yang
Journal:  Gastroenterol Res Pract       Date:  2016-03-16       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.